ROIV FDA approval for oral LISRAYA dermatomyositis therapy
ROIV said the FDA approved LISRAYA as the first oral-targeted therapy for dermatomyositis, launching immediately.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.